CG Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Ivaltinostat for the Treatment of Pancreatic Adenocarcinoma
ORINDA, Calif. and SEOUL, South Korea, Aug. 18, 2022 /PRNewswire/ -- CG Pharmaceuticals, Inc. announced the first patient dosed with the ivaltinostat and capecitabine combination therapy for the Phase1b/2 pancreatic adenocarcinoma (PDAC) maintenance study. Commencement of treatment for the first...
2022-08-18 21:00
1327
CrystalGenomics Appoints Gavin Choy, as President, CG Pharmaceuticals, Inc. to Lead Pipeline Expansion and Global Operations
SEOUL, South Korea, Oct. 7, 2020 /PRNewswire/ -- CrystalGenomics, Inc. (KOSDAQ: 083790), a commercial stage biopharmaceutical company that is dedicated to the discovery, development and commercialization of novel therapeutics in unmet medical need areas of inflammation, oncology, and infectious d...
2020-10-08 08:35
1840
